Contribution of Zranb3 to normal and stressed hematopoiesis
Zranb3 对正常和应激造血的贡献
基本信息
- 批准号:10066914
- 负责人:
- 金额:$ 4.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:ApoptosisB-Cell LymphomasBiochemicalBiologicalBloodBlood CellsBone MarrowBone Marrow CellsCD34 geneCancer cell lineCell DeathCell Differentiation processCell ProliferationCell physiologyCellsCellular StressCessation of lifeDNADNA DamageDNA RepairDNA biosynthesisDNA replication forkDNA strand breakDataDefectDevelopmentDoctor of PhilosophyEmergency SituationEvaluationFailureFamily memberGenesGenomeGenomic InstabilityGenomicsGoalsHematologyHematopoiesisHematopoieticHematopoietic SystemHematopoietic stem cellsHumanInvestigationKnowledgeLeadLifeLymphoidMentorsMusMyelogenousPancytopeniaPathway interactionsPhysiciansPhysiologicalPopulationProcessProliferatingProteinsReportingRoleScientistSourceStimulusStressTestingTrainingUniversitiesbasebiological adaptation to stresscancer cellcareer developmentdefined contributionexperimental studyin vivoin vivo Modelinsightknock-downmouse modelpreferencepreservationpreventprogramsprotective effectreplication stressresponseskillsstem cell proliferationtranscriptome sequencing
项目摘要
Project Summary
Hematopoiesis, the process by which hematopoietic stem and progenitor cells (HSPCs) in the bone marrow
produce all mature blood cells for the hematopoietic system, is required for life. HSPCs are particularly prone to
DNA replication stress due to their high rates of replication during normal hematopoiesis and certainly during
bursts of proliferation from stress-induced/emergency hematopoiesis. DNA replication stress that is not properly
resolved is postulated to contribute to genomic instability and cell death, ultimately leading to HSPC defects,
deficiencies and/or bone marrow failure. Yet, the proteins that mitigate such stress in HSPCs remain largely
uncharacterized. Understanding the proteins that respond to DNA replication stress in HSPCs is essential to
understanding how HSPC development and function is protected throughout a lifetime. Recently, Smarcal1 and
Zranb3, two proteins with the same biochemical activity of fork reversal and remodeling, were determined in
human cancer cells to respond to DNA replication stress and prevent DNA replication fork collapse, but their role
in vivo and in hematopoietic cells remained unexplored. The Eischen lab discovered that while Smarcal1 is not
required for normal hematopoiesis, it is essential for HSPCs during stressed/emergency hematopoiesis.
Currently, little is known about Zranb3 in vivo, as well as whether the functions of Smarcal1 and Zranb3 are
redundant in vivo in hematopoietic cells. Our preliminary data suggest Zranb3 may be essential for HSPCs and
its functions are non-redundant with Smarcal1 in vivo. Therefore, we hypothesize Zranb3 is an essential
component of the DNA replication stress response in HSPCs and significantly contributes to their proliferation
and survival. To test this hypothesis, we will use mouse models and both mouse and human primary
hematopoietic cells. In Aim 1, we propose to investigate the requirements of Zranb3 to normal hematopoiesis
and the mechanism involved. In Aim 2, we will investigate the contribution of Zranb3 to DNA replication stress-
induced during stressed/emergency hematopoiesis. Results from the proposed experiments will significantly
increase understanding of the DNA replication stress response that protects hematopoietic cells during normal
and stressed hematopoiesis and prevents hematopoietic cell failure.
The MD/PhD program at Thomas Jefferson University provides challenging, comprehensive training that
will allow me to fulfill the goals of this application and become a successful independent physician-scientist. My
training will include the development of many skills and an increase of knowledge through multiple approaches
supported by my mentor, thesis committee, and other scientists. The educational and career development
objectives outlined in this proposal will help me fulfill my goal of becoming a successful, independent physician-
scientist focused on hematology.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Saul Kushinsky其他文献
Saul Kushinsky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Saul Kushinsky', 18)}}的其他基金
Contribution of Zranb3 to normal and stressed hematopoiesis
Zranb3 对正常和应激造血的贡献
- 批准号:
10668267 - 财政年份:2020
- 资助金额:
$ 4.68万 - 项目类别:
Contribution of Zranb3 to normal and stressed hematopoiesis
Zranb3 对正常和应激造血的贡献
- 批准号:
10434720 - 财政年份:2020
- 资助金额:
$ 4.68万 - 项目类别:
Contribution of Zranb3 to normal and stressed hematopoiesis
Zranb3 对正常和应激造血的贡献
- 批准号:
10165460 - 财政年份:2020
- 资助金额:
$ 4.68万 - 项目类别:
相似海外基金
Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
- 批准号:
24K19213 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
- 批准号:
23K15982 - 财政年份:2023
- 资助金额:
$ 4.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
- 批准号:
10606730 - 财政年份:2023
- 资助金额:
$ 4.68万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10566833 - 财政年份:2023
- 资助金额:
$ 4.68万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10987699 - 财政年份:2023
- 资助金额:
$ 4.68万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10541285 - 财政年份:2022
- 资助金额:
$ 4.68万 - 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10540952 - 财政年份:2022
- 资助金额:
$ 4.68万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10703446 - 财政年份:2022
- 资助金额:
$ 4.68万 - 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
- 批准号:
22K08497 - 财政年份:2022
- 资助金额:
$ 4.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10707312 - 财政年份:2022
- 资助金额:
$ 4.68万 - 项目类别: